LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $95.25.

LMAT has been the topic of a number of recent research reports. Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price on the stock. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Lake Street Capital raised their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, Oppenheimer cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of LMAT. Creative Planning boosted its holdings in shares of LeMaitre Vascular by 20.7% during the third quarter. Creative Planning now owns 3,594 shares of the medical instruments supplier’s stock worth $334,000 after acquiring an additional 617 shares during the period. Robeco Institutional Asset Management B.V. acquired a new stake in LeMaitre Vascular during the 3rd quarter worth approximately $283,000. Portside Wealth Group LLC bought a new stake in LeMaitre Vascular in the 3rd quarter valued at $497,000. Summit Global Investments grew its holdings in LeMaitre Vascular by 2.4% in the 3rd quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock valued at $575,000 after buying an additional 146 shares in the last quarter. Finally, Atria Investments Inc increased its position in LeMaitre Vascular by 43.9% during the 3rd quarter. Atria Investments Inc now owns 8,853 shares of the medical instruments supplier’s stock worth $822,000 after buying an additional 2,701 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $81.52 on Friday. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of 44.55, a PEG ratio of 2.22 and a beta of 0.89. LeMaitre Vascular has a 52 week low of $62.39 and a 52 week high of $109.58. The stock’s 50 day moving average price is $95.66 and its two-hundred day moving average price is $94.76.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $55.81 million during the quarter, compared to analysts’ expectations of $55.99 million. On average, equities research analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th will be paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date is Thursday, March 13th. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.